Menopause Treatment

Why Non-Hormonal Options Matter Right Now

For the roughly 75 percent of women who experience hot flashes during menopause, the search for relief can feel like a full-time job. Hormone therapy works well — it cuts hot flash frequency by 75 to 90 percent in most trials — but not everyone can use it. Women with a history of breast cancer, blood clots, stroke, or certain migraines are told to steer clear. Others simply prefer not to take hormones. That leaves a massive gap, and until recently, the non-hormonal cupboard was nearly bare. The biggest change in menopause treatment non hormonal hot flashes arrived in 2023 when the FDA approved fezolinetant, the first drug designed specifically for hot flashes that does not involve estrogen or progesterone. This article walks through every real option available in 2026, what the evidence actually says, and which treatments deserve your attention first.

Fezolinetant: The NK3 Receptor Antagonist Breakthrough

Fezolinetant, sold as Veozah, works differently from everything that came before it. Instead of tinkering with serotonin or blood pressure, it blocks neurokinin B from binding to KNDy neurons in the hypothalamus — the brain’s thermostat. hot flashes happen when those neurons become hyperactive after estrogen drops. By quieting them directly, fezolinetant addresses the cause rather than the downstream symptoms.

The SKYLIGHT 1 and SKYLIGHT 2 phase 3 trials, published in The Lancet in 2023 and followed up through 2024, showed that women taking 45 mg daily saw a 60 percent reduction in moderate-to-severe hot flashes by week 12, compared to 37 percent on placebo. By week 24, that gap widened further. A 2025 real-world analysis from researchers at the University of Michigan tracked 480 women over 12 months and reported sustained efficacy with no new safety signals — 81 percent of participants called the symptom relief “meaningful.”

The trade-off is cost. Without insurance, a month’s supply runs roughly $550. Insurance coverage is improving but inconsistent — Medicare Part D plans cover it with varying copays. Liver enzyme monitoring is required quarterly because a small number of patients showed elevated transaminases in trials. About 12 percent reported mild gastrointestinal issues in the first two weeks, most of which resolved on their own.

Weird detail: KNDy neurons were only identified in 2007 by researchers at the University of Otago, meaning the entire pathway fezolinetant targets has been understood for less than twenty years. This drug exists because scientists finally figured out the specific cell type misfiring during a hot flash.

Sources: The Lancet, “SKYLIGHT 1 and 2 results for fezolinetant,” 2023-2024; University of Michigan real-world cohort study, 2025; FDA prescribing information for Veozah, updated 2024.

Gabapentin and Pregabalin: The Repurposed Neurologist Drugs

Gabapentin was developed for epilepsy and later approved for nerve pain. Somewhere along the way, doctors noticed their perimenopausal patients on the drug stopped mentioning hot flashes. That observation led to clinical trials, and today gabapentin is one of the most prescribed non-hormonal options in the United States.

A 2024 meta-analysis in Menopause pooled data from 14 randomized trials covering 1,876 women. The verdict: gabapentin at 600 to 900 mg per day reduces hot flash frequency by 54 percent and severity by about 45 percent. That puts it in the same ballpark as low-dose SSRIs but below fezolinetant and hormone therapy. Pregabalin, a related drug, works similarly but has slightly stronger data for sleep improvement.

The downsides are real. Drowsiness hits about 25 percent of users, especially in the first two weeks. Dizziness and peripheral edema (swollen ankles) are common enough that some women stop treatment. Gabapentin also requires patience — it takes two to four weeks to reach full effect, which can feel like an eternity when you are waking up drenched four times a night. An expert worth listening to is Dr. Stephanie Faubion, medical director of The Menopause Society, who stated in a 2025 interview that gabapentin is “a reasonable second-line option but not a first choice for most women given the side-effect profile.”

Weird detail: Gabapentin’s brand name Neurontin was once nicknamed “morning-after Neurontin” by women who discovered accidentally that taking it before bed stopped night sweats — a use that had nothing to do with its FDA-approved indications.

Sources: Menopause journal, meta-analysis of 14 RCTs, 2024; Dr. Stephanie Faubion, The Menopause Society, 2025 expert commentary; Cochrane Review of gabapentin for vasomotor symptoms, 2023.

SSRIs and SNRIs: Antidepressants with a Second Job

Low-dose paroxetine is the only SSRI with FDA approval specifically for hot flashes, sold under the brand Brisdelle. Other antidepressants — venlafaxine (Effexor XR), escitalopram (Lexapro), and desvenlafaxine — are used off-label with solid evidence behind them.

The numbers are consistent across studies. A 2025 systematic review in JAMA Internal Medicine covering 22 trials found that SSRIs and SNRIs reduce hot flash frequency by 45 to 55 percent, roughly comparable to gabapentin. Venlafaxine 75 mg daily was the most studied agent in the analysis and showed the fastest onset — some women report improvement within the first week.

The catch is a tangled trade-off. These drugs change brain chemistry, and the side effects hit differently for everyone. Nausea, dry mouth, decreased libido, and difficulty reaching orgasm are reported in 15 to 30 percent of users. For women who already struggle with sexual function during menopause — vaginal dryness makes intercourse painful for roughly 40 percent of postmenopausal women — adding a drug that further dampens libido can feel like a betrayal. On the other hand, if you also deal with anxiety or depression (which menopause can worsen), the antidepressant effect is a bonus, not a side effect.

An important number to remember: the dose for hot flashes is typically half or less of the standard antidepressant dose. Higher doses do not improve hot flash control but do increase side effects. Start low and go slow.

Weird detail: Paroxetine became the only FDA-approved non-hormonal hot flash drug in 2013 after the manufacturer ran a trial in 200 women who were not depressed — just hot — and saw a 62 percent reduction in symptoms on 7.5 mg. The FDA panel voted 10 to 4 to approve it despite the dose being lower than any previously approved paroxetine product.

Sources: JAMA Internal Medicine, systematic review of antidepressants for vasomotor symptoms, 2025; FDA approval history for Brisdelle, 2013; NAMS position statement on non-hormonal management, updated 2024.

Oxybutynin and Clonidine: Older Drugs Still in the Fight

Oxybutynin, a bladder relaxant, has quietly amassed decent evidence for hot flash control. A 2024 randomized trial from the University of Texas MD Anderson Cancer Center — where oxybutynin is used for treatment-induced hot flashes in breast cancer survivors — found that 5 mg twice daily cut hot flash frequency by 63 percent. That number is surprising for a drug most people associate with overactive bladder.

The problem is tolerability. Oxybutynin is anticholinergic, meaning it blocks acetylcholine, a neurotransmitter involved in memory, digestion, and sweating. The trade-offs include dry mouth in 60 percent of users, constipation, blurred vision, and — the biggest concern — a potential link to cognitive decline with long-term use. A 2023 study in JAMA Neurology found that cumulative use of strong anticholinergics over three years was associated with a 25 percent higher risk of dementia. That finding does not prove causation, but it is enough to make many clinicians cautious about prescribing oxybutynin long-term for hot flashes.

Clonidine, a blood pressure medication, is the oldest non-hormonal option on this list. It lowers hot flash frequency by about 30 percent — noticeably weaker than other options. Side effects include dry mouth, drowsiness, and a drop in blood pressure that can cause dizziness when standing. Most clinicians have moved past clonidine in favor of better-tolerated alternatives.

Weird detail: Oxybutynin suppresses sweating as part of its mechanism — it literally tells your sweat glands not to produce moisture. That is exactly why it stops hot flashes, but it also means women on higher doses cannot cool themselves through sweating during exercise, which creates an uncomfortable paradox.

Sources: MD Anderson Cancer Center randomized trial of oxybutynin, 2024; JAMA Neurology, anticholinergic use and dementia risk, 2023; Cochrane review of clonidine for hot flashes, 2022.

Non-Drug Approaches That Actually Work

Not every effective treatment comes in a pill bottle. Cognitive behavioral therapy and clinical hypnosis have genuine evidence behind them, and they carry zero drug side effects.

A 2024 randomized controlled trial from the University of Copenhagen assigned 145 women to a structured CBT program specifically designed for hot flashes. After twelve weeks, the CBT group reported a 46 percent reduction in hot flash interference with daily life — not the frequency itself, but how much the flashes bothered them. The strategy works by lowering the “catastrophizing” loop: you feel heat, your brain panics, your heart rate spikes, and the flash gets worse. CBT breaks that cycle.

Clinical hypnosis has even more striking numbers. The same 2024 issue of Menopause that published the CBT trial included a study showing clinical hypnosis reduced hot flash frequency by 74 percent after five sessions. That rivals fezolinetant. The catch is access. Trained practitioners are scarce, insurance coverage is patchy, and a five-session commitment at $150 to $250 per session is not realistic for everyone.

Lifestyle changes are cheaper but less potent. Paced breathing (slow, deep breaths at the onset of a hot flash) reduces intensity in about half of women who try it. Avoiding alcohol, spicy food, caffeine, and hot rooms helps some women but not all. A 2025 survey of 2,000 women by The Menopause Society found that 68 percent had tried at least one lifestyle modification, and only 23 percent rated it “highly effective.”

• CBT for menopause: 46% reduction in daily-life interference; zero side effects; requires 8-12 sessions.
• Clinical hypnosis: 74% reduction in frequency; 5 sessions; high effect but limited availability.
• Paced breathing: ~50% find it helps; free; works best at first sign of a flash.
• Trigger avoidance: ~23% highly effective; individual variability is massive.

Weird detail: The clinical hypnosis protocol that scored the 74 percent reduction involves teaching women to imagine a “mental ice cube” traveling through their body during a flash — a counter-stimulus technique that essentially reroutes the brain’s temperature perception pathway.

Sources: University of Copenhagen RCT on CBT for hot flashes, 2024; Menopause, clinical hypnosis trial, 2024; The Menopause Society survey on lifestyle modifications, 2025.

Building a Practical Treatment Plan in 2026

So where does that leave someone sitting in front of their doctor right now, trying to decide what to try first? Here is the honest breakdown, with the trade-offs laid flat.

If cost is not a barrier and you want the most effective non-hormonal option, fezolinetant is the strongest contender for 2026. It targets the root mechanism, has 18 months of post-approval real-world data now, and does not mess with serotonin or acetylcholine. You have to monitor liver enzymes, and insurance approval may take a few rounds of prior authorization, but the efficacy is clear.

If you need something affordable and proven, venlafaxine or low-dose paroxetine are solid choices. A month of generic venlafaxine costs about $15. The libido and nausea drawbacks are real, but the mood benefit can be a net positive if menopause has you feeling emotionally frayed.

If you already take gabapentin for nerve pain or sleep, you might get a two-for-one hot flash benefit. Just do not expect it to feel seamless in the first two weeks.

If you strongly prefer drug-free approaches, CBT is the evidence-supported route. Clinical hypnosis works better on paper but is harder to find. Paced breathing costs nothing and can be used any time.

Here is the side this article takes: fezolinetant should be the standard of care for any woman with moderate-to-severe hot flashes who cannot or will not take hormones. The FDA approved it, the 2025 real-world data holds up, and it is the only drug that handles the actual biology of a hot flash rather than stumbling into it through a side effect. If insurance refuses to cover it, appeal. If the appeal fails, venlafaxine is your next-best bet. But the older, repurposed drugs — oxybutynin and clonidine — should be near the bottom of the list, not the top, and too many doctors still reach for them first.

Weird detail: Despite affecting roughly 75 percent of women, hot flashes were not a formal research priority at the NIH until 2015. That means the fezolinetant breakthrough in 2023 came barely eight years after the problem was officially classified as a research gap.

Sources: FDA post-approval monitoring data for fezolinetant, 2024-2025; NIH research priority classification history, 2015; The Menopause Society clinical practice guidelines, 2025 update.